AI-generated analysis. Always verify with the original filing.
Illumina announces retirement of three directors effective May 21, 2026, and nominates David P. King for election at the 2026 annual meeting to support growth and innovation.
Illumina's Board changes involve the planned retirement of three experienced directors—Drs. Frances Arnold, Robert S. Epstein, and Gary S. Guthart—effective at the 2026 annual meeting on May 21, 2026, explicitly stated as not resulting from any disagreements. This refreshment nominates David P. King, bringing deep healthcare and life sciences expertise from his prior roles as Executive Chairman and CEO of LabCorp, and current board positions at Privia Health, AmSurg, and Smith & Nephew. Chair Scott Gottlieb highlighted King's operating experience and regulatory insight to advance Illumina's genomics integration into medicine, signaling continuity and strategic evolution for investors.
Event Type
Disclosure
Mandatory
Variant
8-K
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On April
, including Exhibit 99.1 , shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject
Financial Statements and Exhibits. (d) Exhibits. 99.1 Illumina, Inc. Press Release, dated April 2, 2026 104 Cover Page Interactive Data File (embedded within th
Frances Arnold
Effective: 2026-05-21
Notified intention to retire; not due to dispute or disagreement
Robert S. Epstein
Effective: 2026-05-21
Notified intention to retire; not due to dispute or disagreement
Gary S. Guthart
Effective: 2026-05-21
Notified intention to retire; not due to dispute or disagreement
David P. King
Effective: 2026 annual meeting of stockholders